UY37676A - Tratamiento para el asma con anticuerpo anti-tslp - Google Patents

Tratamiento para el asma con anticuerpo anti-tslp

Info

Publication number
UY37676A
UY37676A UY0001037676A UY37676A UY37676A UY 37676 A UY37676 A UY 37676A UY 0001037676 A UY0001037676 A UY 0001037676A UY 37676 A UY37676 A UY 37676A UY 37676 A UY37676 A UY 37676A
Authority
UY
Uruguay
Prior art keywords
asthma
treatment
tslp antibody
tslp
antibody
Prior art date
Application number
UY0001037676A
Other languages
English (en)
Inventor
R Parnes Jane
Janet Griffiths
Original Assignee
Amgen Inc
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Medimmune Llc filed Critical Amgen Inc
Publication of UY37676A publication Critical patent/UY37676A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere, en general, a métodos para tratar el asma, que incluyen asma grave y asma eosinofílico bajo, mediante el uso de un anticuerpo específico para la linfopoyetina estromal tímica (TSLP).
UY0001037676A 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp UY37676A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01

Publications (1)

Publication Number Publication Date
UY37676A true UY37676A (es) 2018-10-31

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037676A UY37676A (es) 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp

Country Status (19)

Country Link
US (2) US10828365B2 (es)
EP (1) EP3609917A1 (es)
JP (2) JP7330896B2 (es)
KR (2) KR102666879B1 (es)
CN (1) CN110573525A (es)
AU (1) AU2018253118A1 (es)
BR (1) BR112019021482A2 (es)
CA (1) CA3059364A1 (es)
CL (1) CL2019002897A1 (es)
CO (1) CO2019011462A2 (es)
IL (1) IL269791B (es)
JO (1) JOP20190243A1 (es)
MX (1) MX2019012158A (es)
PE (1) PE20200484A1 (es)
PH (1) PH12019502331A1 (es)
SG (1) SG11201909322VA (es)
TN (1) TN2019000289A1 (es)
UY (1) UY37676A (es)
WO (1) WO2018191479A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181368A1 (es) * 2015-09-09 2018-08-27 Novartis Ag Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas
EP3981788A4 (en) * 2019-06-04 2023-03-22 Jiangsu Hengrui Medicine Co., Ltd. ANTIBODY CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN AND ITS USE
WO2021007533A1 (en) * 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
EP4025602A4 (en) * 2019-09-04 2023-12-13 Biosion, Inc. TSLP-BINDING ANTIBODIES AND THEIR USES
CR20220189A (es) * 2019-10-28 2022-08-19 Medimmune Ltd Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.
EP4047019A4 (en) * 2019-12-13 2023-11-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ANTI-TSLP ANTIBODIES AND USES THEREOF
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4103605A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
KR20220140772A (ko) * 2020-02-13 2022-10-18 암젠 인크 인간 항-tslp 항체 제형 및 염증성 질환의 치료 방법
IL295511A (en) * 2020-02-18 2022-10-01 Amgen Inc Formulations of human anti-tslp antibodies and methods of using them
TW202229339A (zh) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 結合胸腺基質淋巴細胞生成素的抗體及其應用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
EP4302778A1 (en) * 2021-03-03 2024-01-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition containing anti-tslp antibody
IL307651A (en) * 2021-04-19 2023-12-01 Medimmune Ltd Anti-TSLP FAB with improved stability
BR112023022041A2 (pt) 2021-04-23 2023-12-26 Amgen Inc Anticorpos anti-tslp modificados
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
AR082163A1 (es) * 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
KR20160068802A (ko) * 2013-10-23 2016-06-15 제넨테크, 인크. 호산구성 장애를 진단 및 치료하는 방법
CN107106679B (zh) * 2014-08-08 2022-07-26 艾利妥 抗trem2抗体及其使用方法
RU2017134274A (ru) * 2015-03-11 2019-04-03 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Связывающие tslp белки
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies

Also Published As

Publication number Publication date
CL2019002897A1 (es) 2020-03-06
SG11201909322VA (en) 2019-11-28
JOP20190243A1 (ar) 2019-10-13
PE20200484A1 (es) 2020-03-03
KR20240070727A (ko) 2024-05-21
KR102666879B1 (ko) 2024-05-23
CO2019011462A2 (es) 2019-10-31
IL269791A (en) 2019-11-28
PH12019502331A1 (en) 2020-09-28
TW201838652A (zh) 2018-11-01
IL269791B (en) 2022-07-01
JP2023099233A (ja) 2023-07-11
CN110573525A (zh) 2019-12-13
EP3609917A1 (en) 2020-02-19
AU2018253118A1 (en) 2019-10-24
JP2020516647A (ja) 2020-06-11
CA3059364A1 (en) 2018-10-18
KR20190140956A (ko) 2019-12-20
JP7330896B2 (ja) 2023-08-22
MX2019012158A (es) 2019-12-16
US10828365B2 (en) 2020-11-10
US20180296669A1 (en) 2018-10-18
WO2018191479A1 (en) 2018-10-18
BR112019021482A2 (pt) 2020-05-12
US20210052726A1 (en) 2021-02-25
TN2019000289A1 (en) 2021-05-07

Similar Documents

Publication Publication Date Title
UY37676A (es) Tratamiento para el asma con anticuerpo anti-tslp
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2017000300A2 (es) Moléculas con especificidad para cd45 y cd79
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
BR112017014230A2 (pt) endófitos de semente através de cultivares e espécies, composições associadas e métodos de uso dos mesmos
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR122021000068A8 (pt) Composições e usos em métodos para estimular a eficácia de imunoterapia celular adotiva
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
UY37091A (es) Cepas fúngicas solubilizantes de fosfato
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
CL2023003432A1 (es) Fragmento de union fab de igg1 del anticuerpo anti-tslp
CL2018003167A1 (es) Selección de cepas bacterianas útiles en el tratamiento de alergias.